

**Medical Director, Phase I Program  
Sidney Kimmel Cancer Center – Jefferson Health  
Sarah Cannon Research Institute**

The Sidney Kimmel Cancer Center – Jefferson Health (SKCC), in partnership with Sarah Cannon Research Institute (Sarah Cannon) invites nominations and applications for the position of Medical Director for the Phase I Program.

The Sidney Kimmel Cancer Center – Jefferson Health (SKCC) is one of only 70 NCI-Designated Centers in the United States. Founded in 1991, as a stand-alone cancer center with a staff of 30, the SKCC has grown into a clinical and research enterprise comprising 32 hospitals within the network and practices staffed by hundreds of oncology researchers and physicians from around the globe. Led by Dr. Knudsen, SKCC has distinguished itself nationally through practice-changing discoveries which are rapidly implemented into clinical trials. At present, approximately 20% of Sidney Kimmel Cancer Center patients take advantage of advanced care options through clinical trials. Thomas Jefferson University Hospital, the academic medical center for the Sidney Kimmel Cancer Center, recently ranked as a top 20 hospital by U.S. News & World Report in 2017-2018 for cancer care.

In June 2018, Sidney Kimmel Cancer Center – Jefferson Health and Sarah Cannon Research Institute (Sarah Cannon) announced today a unique collaboration to advance clinical research through an expanded early phase drug development program and investigator-initiated trials, leveraging the strengths of each. The organizations will combine expertise in drug development and research support services, which will expand the menu of clinical trials to patients across the Delaware Valley and beyond. Additionally, Sarah Cannon will provide SKCC-designed clinical trials in sites within their national network.

Recognizing this strategic partnership of “combining the strengths of SKCC and Sarah Cannon’s robust cancer programs, we are bringing together experts who share a mission to advance cancer research so that patients will have greater access to the latest treatment options that focus on personalized care”, Karen E. Knudsen, PhD, Director of the SKCC has identified the urgent need for a physician leader within the SKCC at Jefferson Health. A national search has begun for an innovative physician scientist to lead and serve as **Medical Director for the Phase I Program** to “accelerate drug development both nationally and globally, with the goal of impacting a larger population of patients seeking new therapies.”

Korn Ferry is assisting Sidney Kimmel Cancer Center – Jefferson Health with this important search. Please forward, as soon as possible, applications or nominations of appropriate candidates, in confidence, to:

Tonika Lam, PhD  
c/o: [tonika.lam@kornferry.com](mailto:tonika.lam@kornferry.com)

*The Sidney Kimmel Cancer Center – Jefferson Health and Sarah Cannon Research Institute are Equal Opportunity/Affirmative Action Employers. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information.*